Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verve Therapeutics

5.78
+0.23004.14%
Volume:978.63K
Turnover:5.68M
Market Cap:513.24M
PE:-2.46
High:5.99
Open:5.64
Low:5.60
Close:5.55
Loading ...

Verve Therapeutics Says US FDA Clears Verve-102 IND Application for Premature Coronary Artery Disease

MT Newswires Live
·
Yesterday

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for Verve-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

THOMSON REUTERS
·
Yesterday

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

GlobeNewswire
·
Yesterday

Verve Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
04 Mar

Verve Therapeutics price target lowered to $15 from $17 at RBC Capital

TIPRANKS
·
04 Mar

RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk

MT Newswires Live
·
04 Mar

RBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)

TIPRANKS
·
04 Mar

Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Mar

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Mar

Verve Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
28 Feb

Verve Therapeutics price target raised to $15 from $14 at H.C. Wainwright

TIPRANKS
·
28 Feb

Verve Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
28 Feb

Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
27 Feb

Verve Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
27 Feb

BRIEF-Verve Therapeutics Q4 EPS USD -0.58

Reuters
·
27 Feb

Verve Therapeutics Q4 Collaboration Revenue USD 13.08 Million

THOMSON REUTERS
·
27 Feb